Multi-center Clinical Study of Vanguard XP Bicruciate Knee System
Multi-center Clinical Study of Vanguard XP Bicruciate Knee System
Compare the clinical and patient reported outcomes of the Vanguard XP Knee System to the Vanguard CR Knee System in patients with antero-medial osteoarthritis of the knee with an intact anterior cruciate ligament.
The purpose of the proposed ALLIKAT study (All Ligaments Left in Knee Arthroplasty Trial) is to evaluate the early outcome of a Total Knee Replacement device that retains both cruciate (Vanguard XP) by comparing it with a control group of patients implanted with an established single cruciate retaining device (Vanguard CR). The study also aims to examine short and long term descriptive cohort outcome data. A small preference cohort group of 60 patients receiving the Vanguard XP Knee System will be recruited alongside the RCT group. This data will be used to confirm the external validity of the RCT group and to contribute to the safety data for the British Orthopaedic Association's Beyond Compliance Programme.
Evaluation will include intra-operative and post-operative complications, longer term survivorship and patient reported outcome measures.
Inclusion Criteria:
Exclusion Criteria:
Age under 18 years.
Revision knee replacement surgery.
Rheumatoid Arthritis.
Traumatic aetiology.
History or clinical signs of ACL rupture.
Previous arthroscopy related to ACL injury or reconstruction.
Correction of a flexion contracture that may require extensive resection of distal femur.
Altered pain perception and / or neurologic affection (for example as a complication arising from diabetes).
Unable to consent for themselves.
Patients with language or cognitive issues that may prevent them completing the follow up requirements.
Contraindications for the device:
Relative contraindications include:
ALLIKAT@ndorms.ox.ac.uk00441865227715
ALLIKAT@ndorms.ox.ac.uk00441865737643
Headington, Oxford OX3 7HE, United Kingdom